The anticancer effects of HDAC inhibitors require the immune system

Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFN...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology Ročník 3; číslo 1; s. e27414
Hlavní autoři: West, Alison C, Smyth, Mark J, Johnstone, Ricky W
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Taylor & Francis 01.01.2014
Landes Bioscience
Témata:
anticancer immunity
anticancer therapy
Author's View
epigenetic regulatory agent
HDACi
immunogenic cell death
immunotherapy
anticancer immunity
anticancer therapy
epigenetic regulatory agent
HDACi
immunogenic cell death
immunotherapy
ISSN:2162-402X, 2162-4011, 2162-402X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2162-402X
2162-4011
2162-402X
DOI:10.4161/onci.27414